These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928 [TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer. Fukuda K; Takeuchi S; Arai S; Kita K; Tanimoto A; Nishiyama A; Yano S Cancer Sci; 2020 Jul; 111(7):2374-2384. PubMed ID: 32391602 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip. Tan J; Zhu L; Shi J; Zhang J; Kuang J; Guo Q; Zhu X; Chen Y; Zhou C; Gao X Eur J Pharm Sci; 2024 Aug; 199():106805. PubMed ID: 38763450 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625 [TBL] [Abstract][Full Text] [Related]
17. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731 [TBL] [Abstract][Full Text] [Related]
18. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341 [TBL] [Abstract][Full Text] [Related]
19. [Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells]. Kang XH; Wang K; Wang Y; Zhao HK; Zhang J; Zhao KL; Miao ZH; Xu ZY; Cao F; Gong YB Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):210-215. PubMed ID: 32252199 [No Abstract] [Full Text] [Related]
20. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient. Yang Z; Yang J; Chen Y; Shao YW; Wang X Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]